Retacrit and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Retacrit (epoetin alfa-epbx), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Eliquis, and have Anaemia.

The phase IV clinical study analyzes which people have Disease progression when taking Retacrit. It is created by eHealthMe based on reports of 2,195 people who have side effects when taking Retacrit from the FDA, and is updated regularly.

What is Retacrit?

Retacrit has active ingredients of epoetin alfa-epbx. eHealthMe is studying from 2,196 Retacrit users. Check the latest studies of Retacrit.

What is Disease progression?

Disease progression is found to be associated with 1,800 drugs and 2,257 conditions by eHealthMe. Check the latest studies of Disease progression.

On Aug, 10, 2026

2,195 people reported to have side effects when taking Retacrit.
Among them, 13 people (0.59%) have Disease progression.

Could Retacrit cause Disease progression?

Among these 13 people:

How long have people been on Retacrit when they have Disease progression? *

What is the gender of people who have Disease progression when taking Retacrit? *

female: 90 %
male: 10 %

What is the age of people who have Disease progression when taking Retacrit? *

What are other drugs people take besides Retacrit? *

What are other side effects people have besides Disease progression? *

Dyspnea (difficult or laboured breathing): 3 people, 23.08%
Rectal Haemorrhage (bleeding from anus): 2 people, 15.38%
Spinal Cord Neoplasm (tumour of spinal cord): 1 person, 7.69%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 7.69%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 7.69%
International Normalised Ratio Increased: 1 person, 7.69%
Hepatitis (inflammation of the liver): 1 person, 7.69%
Drug Ineffective: 1 person, 7.69%
Cardiac Arrest: 1 person, 7.69%
Blood Iron Decreased: 1 person, 7.69%

What are the existing conditions these people have? *

Anaemia (lack of blood): 4 people, 30.77%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 7.69%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 7.69%
Nephrogenic Anaemia (anaemia due to kidney disease): 1 person, 7.69%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 7.69%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 7.69%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Retacrit and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Retacrit:

Retacrit (2,196 reports)

Browse all side effects of Retacrit:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,800 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,257 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on epoetin alfa-epbx (the active ingredients of Retacrit) and Retacrit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.